Multiplicom develops, manufactures and commercializes molecular diagnostic assays, provided as kits, which enable personalized medicine. Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE-
IVD certification and it continues to develop and market quality controlled MPS-based assays. Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy. site, located at Galileïlaan 18 in Niel, Belgium, operates a Quality Management System to design, develop, manufacture and distribute CE-IVD products according to ISO 13485:2012. On January 20, 2017, Agilent Technologies acquired Multiplicom N.V. With the completion of the acquisition, the Multiplicom team is a part of the Genomics Division within Agilent’s Diagnostics & Genomics Group.
